NBTX

$29.613.68%1.05

Nanobiotix Adr (NBTX)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$28.56

Offen:

$29.65

24-Stunden-Volumen:

30,400

Relatives Volumen:

0.22

Marktkapitalisierung:

$1.51B

Einnahmen:

$32.72M

Nettoeinkommen (Verlust:

-$27.55M

KGV:

EPS:

-$0.5718

Netto-Cashflow:

-$41.40M

1W Leistung:

-12.86%

1M Leistung:

+14.99%

6M Leistung:

-4.97%

1Y Leistung:

+53.18%

1-Tages-Spanne:

$29.14$30.15

1-Wochen-Bereich:

$27.49$34.11

52-Wochen-Spanne:

$17.42$57.14

Nanobiotix Adr Aktie (NBTX) Unternehmensprofil

Firmenname

Nanobiotix Adr

Sektor

Healthcare

Branche

Biotechnology

Telefon

Adresse

France

Mitarbeiter

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

NBTX-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Nanobiotix Adr Aktie (NBTX) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-09-15	Resumed	Guggenheim	Buy
2026-02-06	Eingeleitet	TD Cowen	Buy
2024-08-28	Eingeleitet	Guggenheim	Buy
2023-12-08	Eingeleitet	Leerink Partners	Outperform
2021-01-06	Eingeleitet	Evercore ISI	Outperform

Finanzdaten der Nanobiotix Adr-Aktie (NBTX)

Es liegen keine Finanzdaten für Nanobiotix Adr (NBTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nanobiotix Adr Aktie (NBTX) Neueste Nachrichten

Oct 24, 2026

NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de deuxième ligne ou plus - GlobeNewswire Inc.

Oct 24, 2026

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma - GlobeNewswire Inc.

Oct 24, 2026

Oct 22, 2026

Nanobiotix (NBTX) Shares Gain 7.00% to $25.83, Pressing Toward $27.12 Resistance - Volatility Smile - https://www.dars.gov.et/

Oct 22, 2026

Oct 20, 2026

Nanobiotix (NBTX) Slips 1.03% to $21.08 as Shares Test Lower Support Zone - Flat Correction - siam.in

Oct 20, 2026

Oct 19, 2026

NBTX Stock Price, Quote & News - Syfe

Oct 19, 2026

Sep 23, 2026

DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026

Oct 11, 2026

NBTX Q2 2026 Earnings: Loss Per ADS Widens Far Beyond Consensus - Earnings Cycle Outlook - https://www.dars.gov.et/

Oct 11, 2026

Oct 07, 2026

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Capex Guidance - dars.gov.et

Oct 07, 2026

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Short-Term Outlook - https://www.dars.gov.et/

Oct 07, 2026

Oct 06, 2026

NBTX Q2 2026 Earnings: Loss Per Share Far Wider Than Expected as Revenue Stays Unreported - Management Guidance Update - https://www.dars.gov.et/

Oct 06, 2026

Oct 04, 2026

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 7.71% - Earnings Volatility Report - https://www.dars.gov.et/

Oct 04, 2026

Sep 30, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.

Sep 30, 2026

Sep 28, 2026

NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 Support - Relative Volume - https://www.siam.in/

Sep 28, 2026

NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 Support - Triangle Correction - dars.gov.et

Sep 28, 2026

Sep 22, 2026

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Annual Earnings Summary - www.dars.gov.et

Sep 22, 2026

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Pre-Announcement Alert - www.dars.gov.et

Sep 22, 2026

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Revenue Miss Report - dars.gov.et

Sep 22, 2026

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Annual Financial Report - dars.gov.et

Sep 22, 2026

Sep 07, 2026

Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe

Sep 07, 2026

Sep 02, 2026

Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga

Sep 02, 2026

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Buyback Announcement Report - dars.gov.et

Sep 02, 2026

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Subscription Growth Report - careplusvn.com

Sep 02, 2026

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Positive Surprise Momentum - www.dars.gov.et

Sep 02, 2026

Sep 01, 2026

Biophytis (BPTS) Peer Comparison – Compare with Others - valueresearchonline.com

Sep 01, 2026

Aug 23, 2026

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Earnings Whisper Number - careplusvn.com

Aug 23, 2026

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Growth Acceleration Report - dars.gov.et

Aug 23, 2026

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Final Results - www.dars.gov.et

Aug 23, 2026

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Healthcare Earnings Report - dars.gov.et

Aug 23, 2026

Aug 18, 2026

Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% Decrease - Downward Estimate Revision - dars.gov.et

Aug 18, 2026

Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% Decrease - Financial Data - www.dars.gov.et

Aug 18, 2026

Aug 15, 2026

NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS Miss - ROE Trend Analysis - careplusvn.com

Aug 15, 2026

NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS Miss - Subscription Growth Report - dars.gov.et

Aug 15, 2026

Aug 14, 2026

Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Time to Buy? - MarketBeat

Aug 14, 2026

Aug 13, 2026

Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants - Stock Titan

Aug 13, 2026

Aug 12, 2026

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Force Index - dars.gov.et

Aug 12, 2026

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Median Line - dars.gov.et

Aug 12, 2026

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Swing Trade Setups - www.dars.gov.et

Aug 12, 2026

Aug 11, 2026

Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's What Happened - MarketBeat

Aug 11, 2026

Aug 02, 2026

Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock Slips - Consensus Beat Rate - careplusvn.com

Aug 02, 2026

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 02, 2026

Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock Slips - Mid-Term Outlook - dars.gov.et

Aug 02, 2026

Jul 29, 2026

Qatar Investment Authority (NBTX) reports 3.53M Nanobiotix ADRs under sole control - Stock Titan

Jul 29, 2026

Jul 20, 2026

Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.4% - What's Next? - MarketBeat

Jul 20, 2026

Jul 15, 2026

Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% Decline - VWAP Bounce - careplusvn.com

Jul 15, 2026

Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% Decline - FRAMA Signal - dars.gov.et

Jul 15, 2026

Jul 13, 2026

Nanobiotix Adr (NBTX)

Nanobiotix Adr Aktie (NBTX) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Nanobiotix Adr Aktie (NBTX) Hochstufungen & Herabstufungen

Finanzdaten der Nanobiotix Adr-Aktie (NBTX)

Nanobiotix Adr Aktie (NBTX) Neueste Nachrichten

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma - GlobeNewswire Inc.

Nanobiotix (NBTX) Shares Gain 7.00% to $25.83, Pressing Toward $27.12 Resistance - Volatility Smile - https://www.dars.gov.et/

Nanobiotix (NBTX) Slips 1.03% to $21.08 as Shares Test Lower Support Zone - Flat Correction - siam.in

NBTX Stock Price, Quote & News - Syfe

DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada

NBTX Q2 2026 Earnings: Loss Per ADS Widens Far Beyond Consensus - Earnings Cycle Outlook - https://www.dars.gov.et/

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Capex Guidance - dars.gov.et

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Short-Term Outlook - https://www.dars.gov.et/

NBTX Q2 2026 Earnings: Loss Per Share Far Wider Than Expected as Revenue Stays Unreported - Management Guidance Update - https://www.dars.gov.et/

NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 7.71% - Earnings Volatility Report - https://www.dars.gov.et/

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.

NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 Support - Relative Volume - https://www.siam.in/

NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 Support - Triangle Correction - dars.gov.et

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Annual Earnings Summary - www.dars.gov.et

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Pre-Announcement Alert - www.dars.gov.et

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Revenue Miss Report - dars.gov.et

NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus Estimate - Annual Financial Report - dars.gov.et

Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe

Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Buyback Announcement Report - dars.gov.et

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Subscription Growth Report - careplusvn.com

NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17% - Positive Surprise Momentum - www.dars.gov.et

Biophytis (BPTS) Peer Comparison – Compare with Others - valueresearchonline.com

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Earnings Whisper Number - careplusvn.com

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Growth Acceleration Report - dars.gov.et

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Final Results - www.dars.gov.et

Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30% - Healthcare Earnings Report - dars.gov.et

Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% Decrease - Downward Estimate Revision - dars.gov.et

Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% Decrease - Financial Data - www.dars.gov.et

NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS Miss - ROE Trend Analysis - careplusvn.com

NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS Miss - Subscription Growth Report - dars.gov.et

Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Time to Buy? - MarketBeat

Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants - Stock Titan

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Force Index - dars.gov.et

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Median Line - dars.gov.et

Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws Interest - Swing Trade Setups - www.dars.gov.et

Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's What Happened - MarketBeat

Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock Slips - Consensus Beat Rate - careplusvn.com

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock Slips - Mid-Term Outlook - dars.gov.et

Qatar Investment Authority (NBTX) reports 3.53M Nanobiotix ADRs under sole control - Stock Titan

Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.4% - What's Next? - MarketBeat

Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% Decline - VWAP Bounce - careplusvn.com

Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% Decline - FRAMA Signal - dars.gov.et

SK hynix Inc. American Depositary Shares (SKHY) Historical Data - Nasdaq

NBTX - Nanobiotix ADR Dividends - Finviz

5NRA Forecast — Price Target — Prediction for 2027 - TradingView

5NRA Forecast — Price Target — Prediction for 2027 - TradingView

NBTX Stock Price, Quote & Chart - ChartMill

Ähnlich wie NBTX